TABLE 6.
The result of ITS analysis of selected medications between branded drugs and generic drugs in the “4 + 7”pilot cities.
| Categories | DDDs (ten thousand) | Expenditures (ten thousand CNY) | DDDc (CNY) | |||
|---|---|---|---|---|---|---|
| Coef. (95%C.I.) | p-value | Coef. (95%C.I.) | p-value | Coef. (95%C.I.) | p-value | |
| Entecavir | ||||||
| Branded drugs | ||||||
| Baseline trend β 1 | −0.24 (−1.25,0.77) | 0.630 | −6.22 (−31.66,19.22) | 0.616 | −0.02 (−0.11,0.06) | 0.602 |
| Change in level β 2 | −2.98 (−15.72,9.76) | 0.631 | −604.63 (−926.31,-282.95) | 0.001 | −5.29 (−6.35,-4.23) | <0.001 |
| Change in slope β 3 | −1.87 (−3.82,0.08) | 0.059 | −52.81 (−101.87,-3.75) | 0.036 | −0.19 (−0.35,-0.02) | 0.028 |
| Constant β 0 | 97.99 (90.31,105.67) | <0.001 | 2657.37 (2464.08,2850.66) | <0.001 | 27.25 (26.60,27.90) | <0.001 |
| Generic drugs | ||||||
| Baseline trend β 1 | 7.16 (−7.27,21.58) | 0.313 | 59.36 (9.13,109.58) | 0.023 | −0.08 (−0.14,-0.03) | 0.004 |
| Change in level β 2 | 525.07 (342.72,707.42) | <0.001 | −3799.79 (−4435.92,-3163.67) | <0.001 | −8.66 (−9.31,-8.00) | <0.001 |
| Change in slope β 3 | −6.79 (−34.61,21.03) | 0.616 | −147.06 (−244.04,-50.08) | 0.005 | −0.04 (−0.14,0.07) | 0.443 |
| Constant β 0 | 388.74 (279.12,498.37) | <0.001 | 4356.54 (3974.49,4738.58) | <0.001 | 11.44 (11.02,11.86) | <0.001 |
| Tenofovir Fumarate | ||||||
| Branded drugs | ||||||
| Baseline trend β 1 | 1.13 (−0.02,2.28) | 0.055 | 1.13 (−0.02,2.28) | 0.055 | 0.00 (−0.06,0.07) | 0.914 |
| Change in level β 2 | −12.01 (−26.55,2.53) | 0.100 | −12.01 (−26.55,2.53) | 0.100 | −3.46 (−4.30,-2.63) | <0.001 |
| Change in slope β 3 | −1.15 (−3.37,1.07) | 0.293 | −1.15 (−3.37,1.07) | 0.293 | −0.15 (−0.28,-0.02) | 0.024 |
| Constant β 0 | 46.48 (37.73,55.24) | <0.001 | 46.48 (37.73,55.24) | <0.001 | 13.32 (12.81,13.84) | <0.001 |
| Generic drugs | ||||||
| Baseline trend β 1 | 3.41 (0.78,6.04) | 0.014 | 42.54 (30.87,54.20) | <0.001 | −0.01 (−0.05,0.03) | 0.574 |
| Change in level β 2 | 109.43 (76.49,142.37) | <0.001 | −473.18 (−620.34,-326.01) | <0.001 | −10.99 (−11.44,-10.55) | <0.001 |
| Change in slope β 3 | 0.20 (−4.88,5.28) | 0.935 | −56.07 (−78.58,-33.56) | <0.001 | −0.08 (−0.15,-0.02) | 0.018 |
| Constant β 0 | 11.82 (−8.21,31.84) | 0.233 | 151.47 (62.77,240.16) | 0.002 | 12.72 (12.44,12.99) | <0.001 |
| Selected medications | ||||||
| Branded drugs | ||||||
| Baseline trend β 1 | 0.89 (−1.15,2.92) | 0.375 | 9.83 (−26.50,46.16) | 0.579 | −0.08 (−0.17,0.01) | 0.087 |
| Change in level β 2 | −14.87 (−40.59,10.85) | 0.242 | −955.25 (−1414.79,-495.70) | <0.001 | −4.21 (−5.34,-3.09) | <0.001 |
| Change in slope β 3 | −3.03 (−6.96,0.90) | 0.124 | −75.24 (−145.31,-5.18) | 0.037 | −0.16 (−0.34,0.01) | 0.065 |
| Constant β 0 | 144.48 (128.99,159.97) | <0.001 | 3272.92 (2996.87,3548.96) | <0.001 | 22.75 (22.06,23.43) | <0.001 |
| Generic drugs | ||||||
| Baseline trend β 1 | 10.59 (−5.95,27.13) | 0.197 | 102.56 (45.58,159.54) | 0.001 | −0.07 (−0.13,-0.02) | 0.015 |
| Change in level β 2 | 633.46 (424.53,842.39) | <0.001 | −4285.32 (−5006.99,-3563.66) | <0.001 | −8.86 (−9.52,-8.20) | <0.001 |
| Change in slope β 3 | −6.46 (−38.36,25.44) | 0.677 | −203.21 (−313.21,-93.21) | 0.001 | −0.05 (−0.16,0.06) | 0.332 |
| Constant β 0 | 400.53 (274.84,526.22) | <0.001 | 4505.03 (4071.67,4938.39) | <0.001 | 11.49 (11.06,11.91) | <0.001 |
ITS: interrupted time series; DDDs: Defined Daily Doses; DDDc: Defined Daily Drug cost; CNY: Chinese Yuan. The bold value meaning was classification of antiviral medications of hepatitis B virus in this study.